首页> 外文期刊>Clinical Pharmacology and Therapeutics >Calcineurin Inhibitors: Pharmacologic Mechanisms Impacting Both Insulin Resistance and Insulin Secretion Leading to Glucose Dysregulation and Diabetes Mellitus
【24h】

Calcineurin Inhibitors: Pharmacologic Mechanisms Impacting Both Insulin Resistance and Insulin Secretion Leading to Glucose Dysregulation and Diabetes Mellitus

机译:钙突蛋白抑制剂:影响胰岛素抵抗和胰岛素分泌的药理机制,导致葡萄糖失调和糖尿病

获取原文
获取原文并翻译 | 示例
           

摘要

Calcineurin inhibitors (CNIs), including tacrolimus and cyclosporine, are immune-modulating agents used in autoimmune disorders, glomerulonephritides, and after transplantation. CNIs are implicated as diabetogenic drugs but the mechanism is not clearly elucidated. Calcineurin is a cytosolic-phosphatase critical for T-lymphocyte activation. Calcineurin is widely distributed in different tissues responsible for glucose-regulation including pancreas, liver, skeletal muscle, adipocytes, brain, and gut. We describe the pharmacologic effects of CNIs in different tissues and impact on glucose regulation.
机译:钙突蛋白抑制剂(CNI),包括Tacrolimus和环孢菌素,是用于自身免疫疾病,肾盂酮肾上腺素和移植后的免疫调节剂。 CNI涉及糖苷药,但没有明确阐明机制。 钙素素是一种胞质 - 磷酸酶对于T淋巴细胞活化至关重要。 钙皮林广泛分布于负责葡萄糖调节的不同组织中,包括胰腺,肝脏,骨骼肌,脂肪细胞,脑和肠道。 我们描述了CNI在不同组织中的药理学作用和对葡萄糖调控的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号